Enzymology TRIZ Cases

Anti-Globo-H antibodies in FFPE immunohistochemistry help identify therapy-eligible patients and monitor response across cancer types.

Immunohistochemistry of tumor biopsies detects low PD-L1 and substantial CLEVER-1 expression to identify patients likely to respond before treatment.

Anti-CEA monoclonal antibodies use specific binding to enable sensitive cancer detection and treatment-response monitoring.

An O-GlcNAc-targeting PKM2 antibody enables accurate breast cancer prognosis prediction.

A gas sensor corrects baseline variation using heating element resistance data for accurate analyte detection.

A bent overflow pipe diverts water flow into an inner well below the operating level.

Quantifying CBX2 expression via immunohistochemistry identifies tumors likely to respond to Aurora kinase A inhibitors, overcoming chemoresistance.

Segmented support portions enable simultaneous use of multiple binding compounds, resolving the trade-off between high sensitivity and device complexity.

Identifying beta amyloid and Staphylococcus aureus in tonsillar samples resolves the trade-off between diagnostic accuracy and invasive procedures.

A diagnostic device uses labeled gold colloid particles to transport analytes through a biphasic substrate for visual detection.

A biodata measurement strip uses light-emitting and light-receiving units to detect reactive portions on the strip surface.

Vertical flow through a compressed conjugate pad enables rapid food-borne pathogen detection within 60 seconds, resolving sensitivity and speed trade-offs.

A diagnostic kit detects Aspergillus antibodies using recombinant RNU, CA, and DPPV antigens.

A recombinant PSL1b lectin specifically binds to alpha(2,6)-linked sialic acid moieties on glycoconjugates.

An aqueous immunoassay buffer combines polyols, saccharides, and non-ionic detergents to enhance specific antibody binding activity.

Segmenting heterogeneous tumor cells by unique marker profiles resolves the contradiction between broad treatment coverage and precise detection accuracy.

Fresh frozen immunohistochemical analysis reduces diagnosis time from weeks to minutes, enabling immediate intraoperative therapeutic decisions.

Positively charged agents neutralize masking effects from negatively charged moieties, enabling accurate detection of human beta-defensins via immunoassays.

Ultrasonic disruption eliminates mixing timing uncertainty, enabling accurate initial binding rate measurement without prolonged data collection.

Novel antibodies bind JWH and CP synthetic cannabinoids to replace complex GC-MS equipment with cost-effective immunoassay kits.

A polymeric-enzyme antibody conjugate enables rapid detection of target analytes in tissue samples through direct catalytic signal generation.

Peripheral reservoirs slow suspension flow via dams, resolving uneven concentration gradients in hemocytometer chambers.

Pharmaceutical compositions targeting microbiota antigens modulate host immune reactivity to address inflammatory disease pathology.

A wavelength limiting filter stabilizes illumination light to ensure accurate image capture of cultured samples.